Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.49 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14605216 | 0.88 | LMNA (0.55) | HRH3LMNAKDM4EABL1HTT | |
| SCHEMBL327068 | 0.86 | HRH3 (0.55) | HRH3LMNAKDM4EABL1HTT | |
| SCHEMBL6140027 | 0.85 | HRH3 (0.58) | HRH3KDM1ALMNAKDM4EABL1 | |
| SCHEMBL14843687 | 0.85 | HRH3 (0.58) | HRH3KDM1ALMNAKDM4EABL1 | |
| SCHEMBL30754007 | 0.85 | HRH3 (0.58) | HRH3KDM1ALMNAKDM4EABL1 | |
| Hydrochloric Acid SCHEMBL5009902 | 0.84 | HRH3 (0.57) | HRH3KDM1ALMNAKDM4EABL1 | |
| Hydrochloric Acid SCHEMBL5221468 | 0.84 | HRH3 (0.57) | HRH3KDM1ALMNAKDM4EABL1 | |
| SCHEMBL31747419 | 0.83 | HRH3 (0.55) | HRH3KDM1ALMNAKDM4EABL1 | |
| SCHEMBL3544514 | 0.82 | LMNA (0.55) | LMNAKDM4EABL1HTTUSP30 | |
| SCHEMBL5223723 | 0.82 | HRH3 (0.65) | HRH3KDM1AJAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346786-B2 | Pyrrolidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9226916-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| EP-2513084-B1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| EP-2513052-B1 | PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | disclosed |
| US-20130203728-A1 | PYRROLIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130184249-A1 | PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2513084-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-2513052-A1 | PYRROLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| CN-102656157-A | Pyrrolidine derivatives as NK-3 receptor antagonists | HOFFMANN LA ROCHE | 2012-09-05 | — | — | CN | disclosed |
| WO-2011085886-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011073160-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | TACR1, OPRL1, SLC6A3 | HRH3 201/4885KDM1A 1921/4885LMNA 4722/4885 |
| US-20130203728-A1 | PYRROLIDINE COMPOUNDS | SLC6A3, OPRL1, OPRK1 | HRH3 235/4885KDM1A 2499/4885LMNA 4701/4885 |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | SLC6A3, OPRL1, OPRK1 | HRH3 235/4885KDM1A 2499/4885LMNA 4701/4885 |
| US-20130184249-A1 | PYRROLIDINE DERIVATIVES | TACR1, OPRL1, SLC6A3 | HRH3 201/4885KDM1A 1921/4885LMNA 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.